Top Markets
Coin of the day
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
Κατάταξη σε μετοχές #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Τιμή μετοχής
$0.15
Κεφαλαιοποίηση
$4.96M
Αλλαγή (1 ημέρα)
0.00%
Αλλαγή (1 έτος)
0.00%
Χώρα
CA
Εμπόριο Intellipharmaceutics International Inc. (IPCIF)

Κατηγορία

EPS για Intellipharmaceutics International Inc. (IPCIF)
EPS στις August 2023 TTM: $-0.10
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή της μετοχής της Intellipharmaceutics International Inc., το τρέχον EPS της εταιρείας (TTM) είναι $-0.10. Στο τέλος του 2021, η εταιρεία είχε EPS $-0.10, μείωση σε σύγκριση με το EPS του 2020 που ήταν $-0.22.
Ιστορικό EPS της Intellipharmaceutics International Inc. από 1999 έως 2026
EPS στο τέλος κάθε έτους
Έτος EPS Αλλαγή
2026 (TTM) $-0.10 6.44%
2022 $-0.09 -11.09%
2021 $-0.10 -55.32%
2020 $-0.22 37.50%
2019 $-0.16 -94.44%
2018 $-2.88 0.00%
2017 $-2.88 -24.21%
2016 $-3.80 21.41%
2015 $-3.13 87.43%
2014 $-1.67 -71.40%
2013 $-5.84 64.04%
2012 $-3.56 9.54%
2011 $-3.25 -38.45%
2010 $-5.28 -8.65%
2008 $-5.78 -60.38%
2007 $-14.59 -77.93%
2006 $-66.11 -34.18%
2005 $-100.44 9.95%
2004 $-91.35 128.38%
2003 $-40.00 55.16%
2002 $-25.78 26.50%
2001 $-20.38 37.24%
2000 $-14.85 -19.64%
1999 $-18.48 0.00%
EPS για παρόμοιες εταιρείες ή ανταγωνιστές
Εταιρεία EPS Διαφορά EPS Χώρα
$3.62 -3,881.11%
DK
$15.47 -16,248.23%
US
$43.12 -45,110.44%
US
$9.62 -10,142.59%
BE
$38.32 -40,100.00%
NL